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This study compared the effects on glycaemic variability and glucose control between
saxagliptin and acarbose as add-on therapies for aged T2DM inadequately controlled with
metformin alone. The results showed that compared with acarbose–metformin, saxaglip-
tin–metformin was more effective in glucose control with similar glycaemic variability.
# 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Glycaemic variability (GV) is an HbA1c-independent risk factor
in the development of diabetic complications [1]. It should be* Corresponding author. Tel.: +86 20 85253408; fax: +86 20 85252160.
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Abbreviations: GV, glycaemic variability; HbA1c, glycosylated hemo
SMBG, self-monitoring of blood glucose; IDF, International Diabetes Fe
amplitude of glycaemic excursions; DPP-4, dipeptidylpeptidase-4.
http://dx.doi.org/10.1016/j.diabres.2015.02.022
0168-8227/# 2015 The Authors. Published by Elsevier Ireland Ltd. This
creativecommons.org/licenses/by-nc-nd/4.0/).considered along with HbA1c in the management of diabetes
[2]. As an add-on drug, acarbose is known to improve GV [3,4].
Saxagliptin is a new anti-diabetic drug, whose effect on GV is
still unclear. Therefore we compared the GV and glucose
control between saxagliptin and acarbose as add-on therapiesglobin; T2DM, type 2 diabetes mellitus; FBG, fasting blood glucose;
deration; SDBG, standard deviation of blood glucose; LAGE, largest
 is an open access article under the CC BY-NC-ND license (http://
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 8 ( 2 0 1 5 ) e 6 7 – e 7 0e68for aged type 2 diabetes mellitus (T2DM) inadequately
controlled with metformin alone.
2. Research design and methods
Ninety outpatients aged over 60 years, with FBG >8.5 mmol/L
and HbA1c >7.5% (58 mmol/mol) while treated metformin
alone for more than six months, were enrolled. Patients were
excluded if they had acute complications or other disorders
affecting glucose metabolism. The protocol and informed
consent document were approved by the Research Ethics
Board of the Third Affiliated Hospital of Sun Yat-Sen
University.
After enrollment, patients were randomized to saxagliptin
5 mg once daily or acarbose 50 mg three times daily for
one year. Seven-point finger blood glucoses (fasting, 2 h after
breakfast, pre-lunch, 2 h after lunch, pre-dinner, 2 h after
dinner, and pre-bedtime) were measured by self-monitoring
of blood glucose (SMBG) on three consecutive days at
randomization, the 3rd month, the 6th month, and the end
of the study. At the same time physical examinations and
laboratory tests were undertaken.
Non-normally distributed variables were log-transformed
first. Paired t-test was performed to examine differencesFig. 1 – Comparison of HbA1c and FBG between baseline and post-intervention. For the assessment
of differences between two groups, t-test was performed. Chi-
square test was used to analyze the differences of incidence of
hypoglycaemia and rates of HbA1c <7.0% (53 mmol/mol)
between two groups.
3. Results and discussion
Of the ninety patients randomized, eighty-one (90.0%) patients
(forty-one in saxagliptin and forty in acarbose) completed the
study (supplementary data 1). Two groups were similar at
randomization for all variables. After adding saxagliptin or
acarbose, weight, hepatic and renal function did not change.
Insulin resistance (HOMA-IR), b-cell function (HOMA-b), and
lipid metabolism seemed to ameliorate but without signifi-
cance. These improvements were more obvious in saxaglip-
tin than in acarbose but of no significance (supplementary
data 2). During the study, there were no severe hypoglycaemic
episodes-an event requiring another person’s assistance. The
proportion of patients with minor hypoglycaemia-defined as
having finger blood glucose level below 3.9 mmol/L and
prompt recovery after self-administered carbohydrate-was
higher in saxagliptin (4.88%, 2 of 41) than in acarbose (0.00%, 0
of 40) (P > 0.05).between saxagliptin and acarbose.
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 8 ( 2 0 1 5 ) e 6 7 – e 7 0 e69HbA1c and FBG decreased markedly in both groups. This
reduction was more noticeably in saxagliptin than in acarbose
(P < 0.05) (Fig. 1). More patients reached HbA1c <7.0%
(53 mmol/mol), which is recommended by IDF [5], in sax-
agliptin (7.32%, 3 of 41) than in acarbose (2.50%, 1 of 40)
(P > 0.05) (supplementary data 1). Standard deviation of blood
glucose (SDBG) and largest amplitude of glycaemic excursions
(LAGE) decreased significantly with similar end point levels in
both groups (P > 0.05). Adding saxagliptin or acarbose, both
blood glucose curves flatted. The curves of two combinations
were similar in fluctuation at each designated corresponding
time, respectively (Fig. 2).
GV is another sign of dysglycaemia. Clinical studies reveal
GV is a significant predictor of mortality in T2DM [6,7]. In
cellular consequences, intermittent high glucose stimulates a
more reactive oxygen species overproduction, a greater
adhesion molecules overexpression, and an extra cell apopto-
sis than constant high glucose [8–10]. As a result, GV is
regarded as an important risk factor in the development of
diabetic complications. Our results confirmed previously
published papers reporting that acarbose reduced GV
[3,4,11]. Saxagliptin is a dipeptidylpeptidase-4 (DPP-4) inhibi-
tor, which increases glucose-dependent insulin secretion and
suppresses glucagon secretion [12]. Consequently it mainly
targets postprandial hyperglycaemia. As a result, saxagliptin
decreases GV effectively just like acarbose. The present studyFig. 2 – Comparison of SDBG, LAGE, and blood glusuggested that saxagliptin was more effective in lowering
HbA1c and FBG than acarbose. This may lie in its insulin-
stimulated property. Studies indicate that insulin secretago-
gues reduce overall glycaemia and FBG superior to acarbose
[3,13]. Other reports show DPP-4 inhibitors are non-inferior to
insulin secretagogues [14,15]. Furthermore, DDP-4 inhibitors
have various effects on b-cell: stimulating b-cell production;
inhibiting b-cell apoptosis and restoring islet cell mass
[12,16,17]. Moreover, DDP-4 inhibitors have effects on the
gastrointestinal tract: promoting satiety, suppressing food
intake and delaying gastric emptying. All of these may
contribute to saxagliptin’s more effective in reducing HbA1c
and FBG. Other studies report DPP-4 inhibitors and a-
glucosidase inhibitors have similar glucose-lowering effect
[18,19]. This discrepancy may be attributed to the different
subjects as well as different background treatments. For
example, it is reported DPP-4 inhibitors are more efficacious in
the Asians [20].
This study had some limitations. First a 7-point glycaemic
feature could not comprehensively represent the glycaemic
profile of a whole day. Furthermore we did not use the test
meal. The patients’ glucose levels could be influenced.
However, we collected data on three consecutive days but
not on one day, which could lessen the influence. In addition,
the data of daily life instead of load test could rather
successfully reflect ‘‘real world’’ in clinical practice. Finallycose curve between saxagliptin and acarbose.
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 8 ( 2 0 1 5 ) e 6 7 – e 7 0e70the study indicated some results between saxagliptin and
acarbose, but gave little insight as to the mechanism. Further
studies are required to validate the present results and
investigate the mechanism.
4. Conclusions
In aged T2DM inadequately controlled with metformin alone,
saxagliptin–metformin has similar effect on glucose excursion
with acarbose–metformin, and the former has a stronger
effect on glucose control than the latter.
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